内科学講座　腫瘍内科学部門


お知らせ

more

講座員

教員（専任）

役職氏名name
特任教授角田　卓也Tsunoda Takuya
教授堀池　篤Horiike Atsushi
准教授久保田　祐太郎Kubota Yutaro
講師有泉　裕嗣Ariizumi Hirotsugu
講師
下川　雅弘Shimokawa Masahiro
講師
池田　剛Ikeda Go
講師
大熊　遼太朗Ohkuma Ryotaro
助教（医科）
吉澤　孝浩
Yoshizawa Takahiro
助教（医科）平澤　優弥（留学中）Hirasawa Yuya
助教（医科）石黒　智之（留学中）Ishiguro Tomoyuki
非常勤医師
入口　菜々Iriguchi Nana
助教（医科）
鈴木　梨沙子Suzuki Risako
助教（医科）鶴井　敏光Tsurui Toshiaki
助教（医科）村　英美子　（出向中）Mura Emiko

教員（兼任）

役職氏名name
客員教授佐々木　康綱Sasaki Yasutsuna
客員教授山本　信之Yamamoto Nobuyuki
客員教授鈴木　弘行
Suzuki Hiroyuki
客員教授
田中　浩明Tanaka Hiroaki
客員教授
白井　宏樹Shirai Hiroki
兼担
吉村　清Yoshimura Kiyoshi
兼担和田　聡Wada Satoshi
客員講師韓　啓司Onishi Hideki
兼担小島　康幸
Yasuyuki Kojima
兼任講師砂川　優Sunakawa Yu
併任
髙栁　大輔
Takayanagi Daisuke



研究業績

すべて開く　＋
2024年業績

論文（原著）

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study.Tsurui T, Hamada K, Mura E, Suzuki R, Iriguchi N, Ishiguro T, Hirasawa Y, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Wada S, Yoshimura K, Tsuji M, Kiuchi Y, Tsunoda T. Front Oncol. 2025 Feb 6;15:1499650. doi: 10.3389/fonc.2025.1499650. eCollection 2025.

Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors.
Ishiguro T, Takeda K, Takayanagi D, Mura E, Suzuki R, Tsurui T, Iriguchi N, Hirasawa Y, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Izumizaki M, Wada S, Yoshimura K, Hoffman RM, Tsunoda T. Cancer Genomics Proteomics. 2025 Jan-Feb;22(1):1-12. doi: 10.21873/cgp.20481.

Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in mice. Funayama E, Hosonuma M, Tajima K, Isobe J, Baba Y, Murayama M, Narikawa Y, Toyoda H, Tsurui T, Maruyama Y, Sasaki A, Amari Y, Yamazaki Y, Nakashima R, Uchiyama J, Nakano R, Shida M, Sasaki A, Udaka Y, Oguchi T, Sambe T, Kobayashi S, Tsuji M, Kiuchi Y, Kim YG, Wada S, Tsunoda T, Akiyama M, Nobe K, Kuramasu A, Yoshimura K.BiomedPharmacother2025Jan:182:117749.doi:10.1016/j.biopha.2024.117749. Epub 2024 Dec 23.

Relationship between the combination of platelet count and neutrophil-lymphocyte ratio and prognosis of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study. Kashimura S, Sato M, Inagaki T, Kin M, Manabe R, Kusumoto S, Horiike A, Tsunoda T, Kogo M.Thoracic Cancer. 2024 Dec;15(28):2049–2060. doi: 10.1111/1759-7714.15234.

Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patients.
Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Horiike A, Wada S, Yamashita T, Ariyoshi T, Goto S, Otsuka K, Murakami M, Kiuchi Y, Yoshimura K, Tsunoda T.Frontiers in Oncology. 2024 Oct 11:14:1449941. doi: 10.3389/fonc.2024.1449941. eCollection 2024.

MHC class I polypeptide-related sequence B shedding modulates pancreatic tumor immunity via the activation of NKG2D^Low^ T cells.Toyoda H, Kuramasu A, Hosonuma M, Murayama M, Narikawa Y, Isobe J, Baba Y, Tajima K, Funayama E, Shida M, Maruyama Y, Sasaki A, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Kobayashi S, Horiike A, Hida N, Sambe T, Nobe K, Wada S, Kobayashi H, Tsuji M, Kobayashi S, Tsunoda T, Kudo Y, Kiuchi Y, Yoshimura K.Scientific Reports. 2024 Oct;14(1):23401. doi: 10.1038/s41598-024-73712-1.

Clinical utility of pegfilgrastim on day 3 of preoperative docetaxel, cisplatin and -fluorouracil chemotherapy in elderly patients with resectable esophageal cancer.Ikeda G , Yamamoto S , Azuma I , Kadono T , Ohara A , Itoyama M , Hirose T , Yokoyama K , Honma Y , Hashimoto T , Sekine S , Ishiyama K , Oguma J , Daiko H , Iwakiri K , Kato KAnnals of Esophagus.2024;7:18 | https://dx.doi.org/10.21037/aoe-24-20

Maximum efficacy of immune checkpoint inhibitors occurs in esophageal cancer patients with a low neutrophil-to-lymphocyte ratio and good performance status prior to treatment.
Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Horiike A, Wada S, Ariyoshi T, Goto S, Otsuka K, Murakami M, Kiuchi Y, Yoshimura K, Hoffman RM, Tsunoda T.Anticancer Research. Anticancer Res. 2024 Aug;44(8):3397-3407. doi:10.21873/anticanres.17160.

Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model.Kubota Y, Aoki Y, Masaki N, Obara K, Hamada K, Han Q, Bouvet M, Tsunoda T, Hoffman RM. Biochemical and Biophysical Research Communications. 2024 Jul;695:149418. doi: 10.1016/j.bbrc.2024.149418.

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody. Murayama M, Hosonuma M, Kuramasu A, Kobayashi S, Sasaki A, Baba Y, Narikawa Y, Toyoda H, Isobe J, Funayama E, Tajima K, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Hamada K, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kobayashi S, Shimane T, Tsunoda T, Kobayashi H, Kiuchi Y, Yoshimura K.
Scientific Reports. 2024 May 17;14(1):11325. doi: 10.1038/s41598-024-59677-1.

Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.
Yoshimaru Y, Nagaoka K, Tanaka K, Narahara S, Inada H, Kurano S, Tokunaga T, Iio E, Watanabe T, Setoyama H, Tateyama M, Yoshida K, Tsunoda T, Nakamura Y, Tanaka M, Sasaki Y, Tanaka Y.Hepatology Research. 2024 May;54(5):451-464. doi: 10.1111/hepr.13995. Epub 2023 Dec 27.

Efficacy of recombinant methioninase on late-stage patient cancer in the histoculture drug response assay as a potential functional biomarker of sensitivity to methionine-restriction therapy in the clinic.Kubota Y, Sasaki M, Han Q, Hozumi C, Tsunoda T, Hoffman RM.
Cancer Diagnosis & Prognosis. 2024 May-Jun;4(3):239–243. doi: 10.21873/cdp.2024.239.

Methionine dependence of hair maintenance in C57BL/6 mice. Kubota Y, Varshney N, Kobayashi K, Tsunoda T, Hoffman RM.In Vivo. 2024 May;38(3):1199–1202 . doi: 10.21873/invivo.14462

Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma　Go Ikeda, Jun Miyakoshi, Shun Yamamoto, Ken Kato. Future Oncol. 2024 Apr;20(11):665-677. doi: 10.2217/fon-2022-1092. Epub 2023 Dec 21.

2023年業績

論文（原著）

Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report. Tsurui T, Hirasawa Y, Kubota Y, Yoshimura K, Tsunoda T. World Journal of Gastrointestinal Oncology. World Journal of Gastrointestinal Oncology. 2024 Feb;16(2):557–562. doi: 10.4251/wjgo.v16.i2.557.

Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer. Otsuka K, Isobe J, Asai Y, Nakano T, Hattori K, Ariyoshi T, Yamashita T, Motegi K, Saito A, Kohmoto M, Hosonuma M, Kuramasu A, Baba Y, Murayama M, Narikawa Y, Toyoda H, Funayama E, Tajima K, Shida M, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Horiike A, Goto S, Murakami M, Kim YG, Tsunoda T, Yoshimura K. Cancer Immunology, Immunotherapy. 2024 Jan 27;73(2):23. doi: 10.1007/s00262-023-03608-y.

Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.
Hosonuma M, Hirasawa Y, Kuramasu A, Murayama M, Narikawa Y, Toyoda H, Baba Y, Isobe J, Funayama E, Tajima K, Shida M, Hamada K, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Tsunoda T, Yoshimura K.Cancer Science. 2024 Jan;73:23. doi: 10.1007/s00262-023-03645-7.

Precise non-invasive imaging mouse model of pancreatic cancer using very narrow band-width laser fluorescence excitation.
Kubota Y, Wang A, Chang N, Tarantino S, Gallagher S, Aoki Y, Masaki N, Obara K, Morinaga S, Tsunoda T, Hoffman RM. Cancer Diagnosis & Prognosis. . 2024 Jan;4(1):30–33. doi: 10.21873/cdp.20412.

Non-classical monocytes enhance the efficacy of immune checkpoint inhibitors on colon cancer in a syngeneic mouse model. Goshima T, Ieguchi K, Onishi N, Shimizu T, Takayanagi D, Watanabe M, Fujimoto Y, Ohkuma R, Suzuki R, Tsurui T, Mura E, Iriguchi N, Ishiguro T, Shimokawa M, Hirasawa Y, Kubota Y, Ariizumi H, Horiike A, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Fujishiro J, Hoffman RM, Tsunoda T, Wada S.
Anticancer Research. 2024 Jan;44(1):23-29. doi: 10.21873/anticanres.16784.

[^11^C]methionine PET imaging as a cancer biomarker for methionine addiction.
Kubota Y, Sato T, Han Q, Hozumi C, Morinaga S, Mizuta K, Tsunoda T, Hoffman RM.
In Vivo. 2024 Jan-Feb;38(1):253-258. doi: 10.21873/invivo.13432.

Non-invasive fluorescence imaging of breast cancer brain metastasis with very narrow band-width laser excitation. Kubota Y, Aoki Y, Wang A, Chang N, Tarantino S, Gallagher S, Tsunoda T, Hoffman RM. In Vivo. 2024 Jan-Feb;38(1):69-72. doi: 10.21873/invivo.13411.

Case of Imatinib Susceptibility to CYP3A4-Mediated Drug-Drug Interactions in a Patient With Gastrointestinal Stromal Tumor. Fujimiya T, Sugita H, Kin M, Funakoshi H, Kubota Y, Tsunoda T. American Journal of Therapeutics. 2024 Jan-Feb;31(1):e66-e69. doi: 10.1097/MJT.0000000000001535.

Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis. Shimizu T, Inoue E, Ohkuma R, Kobayashi S, Tsunoda T, Wada S. Frontiers in Immunology.2023 Nov 23:14:1308381. doi: 10.3389/fimmu.2023.1308381.

Recombinant-methioninase-producing Escherichia coli instilled in the microbiome inhibits triple-negative breast cancer in an orthotopic cell-line mouse model. Kubota Y, Han Q, Morinaga S, Mizuta K, Bouvet M, Tsunoda T, Hoffman RM. Cancer Diagnosis & Prognosis. 2023 Nov 3;3(6):649-654. doi: 10.21873/cdp.10267..

Recombinant methioninase lowers the effective dose of regorafenib against colon-cancer cells: A strategy for widespread clinical use of a toxic drug.
Choobin BB, Kubota Y, Han Q, Ardjmand D, Morinaga S, Mizuta K, Bouvet M, Tsunoda T, Hoffman RM. Cancer Diagnosis & Prognosis. 2023 Nov 3;3(6):655-659. doi: 10.21873/cdp.10268.

Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors. Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, Onishi N, Shimizu T, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Mura E, Takenoshita S, Numajiri K, Okabe N, Yoshimura K, Tsuji M, Kiuchi Y, Yajima T, Ishida H, Suzuki H, Yamochi T, Kobayashi S, Tsunoda T, Wada S. Frontiers in Immunology. 2023 Sep 18:14:1260492. doi: 10.3389/fimmu.2023.1260492.

Rapid reduction of CEA and stable metastasis in an NRAS-mutant rectal-cancer patient treated with FOLFIRI and bevacizumab combined with oral recombinant methioninase and a low-methionine diet upon metastatic recurrence after FOLFIRI and bevacizumab treatment alone. Kubota Y, Han Q, Morinaga S, Tsunoda T, Hoffman RM.
In Vivo. 2023 Sep-Oct;37(5):2134-2138. doi: 10.21873/invivo.13310.

Monocyte subsets associated with the efficacy of anti-PD-1 antibody monotherapy.
Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Sasaki Y, Homma M, Yamochi T, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S. Oncol Lett. 2023 Jul 20;26(3):381. doi: 10.3892/ol.2023.13967. eCollection 2023 Sep.

2022年業績

論文（原著）　　

Case report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary.
Suzuki R, Hamada K, Ohkuma R, Homma M, Tsurui T, Iriguchi N, Ishiguro T, Hirasawa Y, Ariizumi H, Kubota Y, Horiike A, Yoshimura K, Wada S, Yamochi T, Tsunoda T.
Front Oncol. 2023 Jul 10;13:1231986. doi: 10.3389/fonc.2023.1231986.

Old-age-induced obesity reversed by a methionine-deficient diet or oral administration of recombinant methioninase-producing Escherichia coli in C57BL/6 mice. Kubota Y, Han Q, Reynoso J, Aoki Y, Masaki N, Obara K, Hamada K, Bouvet M, Tsunoda T, Hoffman RM.
Aging (Albany NY). 2023 Jun 9;15(11):4642-4648. doi: 10.18632/aging.204783.
PMCID: PMC10292902

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor. Hamada K, Isobe J, Hattori K, Hosonuma M, Baba Y, Murayama M, Narikawa Y, Toyoda H, Funayama E, Tajima K, Shida M, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Kuramasu A, Horiike A, Kim YG, Tsunoda T, Yoshimura K. Front Immunol. 2023 May 3;14:1164724. doi: 10.3389/fimmu.2023.1164724.

Synergy of combining methionine restriction and chemotherapy: The disruptive next generation of cancer treatment. Kubota Y, Han Q, Aoki Y, Masaki N, Obara K, Hamada K, Hozumi C, Wong ACW, Bouvet M, Tsunoda T, Hoffman RM. Cancer Diagn Progn. 2023 May 3;3(3):272-281. doi: 10.21873/cdp.10212.

Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02). Hasegawa T, Ariyasu R, Tanaka H, Saito R, Kawashima Y, Horiike A, Sakatani T, Tozuka T, Shiihara J, Saiki M, Tambo Y, Sonoda T, Miyazaki A, Uematsu S, Tsuchiya-Kawano Y, Yanagitani N, Nishino M. Cancer Chemother Pharmacol. 2023 Jul;92(1):29–37. doi: 10.1007/s00280-023-04547-2. Epub 2023 May 27.

Superiority of [^11^C]methionine over [^18^F]deoxyglucose for PET imaging of multiple cancer types due to the methionine addiction of cancer. Kubota Y, Sato T, Hozumi C, Han Q, Aoki Y, Masaki N, Obara K, Tsunoda T, Hoffman RM. International Journal of Molecular Sciences. 2023 Jan 18;24(3):1935. doi: 10.3390/ijms24031935.

[Comparison of Current Perspectives of Perioperative Treatments for Esophageal Cancer between Japan and the Western Countries-Toward International Collaborative Studies].
Go Ikeda, Shun Yamamoto, Ken Kato Comparative Study Gan To Kagaku Ryoho. 2023 Jan;50(1):18-22.

Elimination of axillary-lymph-node metastases in a patient with invasive lobular breast cancer treated by first-line neoadjuvant chemotherapy combined with methionine restriction.
Kubota Y, Han Q, Masaki N, Hozumi C, Hamada K, Aoki Y, Obara K, Tsunoda T, Hoffman RM. Anticancer Research. 2022 Dec;42(12):5819–5823. doi: 10.21873/anticanres.16127.

Fine-needle biopsy with 19G needle is effective in combination with endoscopic ultrasound-guided tissue acquisition for genomic profiling of unresectable pancreatic cancer
Go Ikeda, Susumu Hijioka, Yoshikuni Nagashio, Yuta Maruki, Akihiro Ohba, Yuya Hisada, Motohiro Yoshinari, Shota Harai, Hidetoshi Kitamura, Takehiko Koga, Yumi Murashima, Kosuke Maehara, Mao Okada, Daiki Yamashige, Kohei Okamoto, Hidenobu Hara, Yuya Hagiwara, Daiki Agarie, Tetsuro Takasaki, Kotaro Takeshita, Yuki Kawasaki, Shunsuke Kondo, Chigusa Morizane, Hideki Ueno, Nobuyoshi Hiraoka, Yasushi Yatabe, Yutaka Saito, Katsuhiko Iwakiri, Takuji Okusaka Dig Endosc. 2023 Jan;35(1):124-133. doi: 10.1111/den.14423. Epub 2022 Sep 13.

Future prospects for cancer immunotherapy – Strategies for ineffective cancers.
Wada S, Kobayashi S, Tsunoda T.Human Vaccines & Immunotherapeutics. 2022 Dec 31;18(1):2031699. doi: 10.1080/21645515.2022.2031699. Epub 2022 Jan 25.

A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report. Hamada K, Yoshimura K, Oshinomi K, Hirasawa Y, Ariizumi H, Ohkuma R, Shida M, Kubota Y, Matsui H, Ishiguro T, Sambe T, Ishida H, Horiike A, Wada S, Iwamoto S, Uchida N, Ogawa Y, Kobayashi S, Tsunoda T.
Medicine (Baltimore). 2022 Jan 14;101(2):e28339. doi: 10.1097/MD.0000000000028339.

The PD-L1/22C3 assay for primary lung cancer is feasible for daily clinical practice irrespective of the diagnostic procedure.Suganuma H, Kusumoto S, Manabe R, Kishino Y, Endo T, Ando K, Ishida H, Horiike A, Tanaka A, Takei H, Yamochi T, Tsunoda T, Sagara H.
Showa University Journal of Medical Sciences. 2022 Dec;34(2):64–77. doi: 10.15369/sujms.34.64.

A case of cerebral infarction during treatment with rivaroxaban for venous thromboembolism.
Kitahara K, Momo K, Nimura S, Okazaki K, Suzuki N, Kubota Y, Tsunoda T, Watanabe D, Mizuma K, Ono K, Sasaki T. American Journal of Therapeutics. 2022 Nov-Dec;29(6):e673-e676. doi: 10.1097/MJT.0000000000001312.

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: A prospective study. Nio Y, Ishida H, Matsumoto N, Kusumoto S, Kubota Y, Tsunoda T, Sasaki Y, Fujita KI. BMC Pulmonary Medicine. 2022 Nov 30;22:454. doi: 10.1186/s12890-022-02249-8

Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors. Uematsu S, Kitazono S, Tanaka H, Saito R, Kawashima Y, Ohyanagi F, Tozuka T, Ryosuke T, Sakatani T, Horiike A, Yoshizawa T, Saiki M, Tambo Y, Koyama J, Kanazu M, Kudo K, Tsuchiya-Kawano Y, Yanagitani N, Nishio M. Thorac Cancer. 2023 Jan;14(2):168–176. doi: 10.1111/1759-7714.14729. Epub 2022 Nov 21.

Oral installation of recombinant methioninase-producing Escherichia coli into the microbiome inhibits colon-cancer growth in a syngeneic mouse model.
Kubota Y, Han Q, Hamada K, Aoki Y, Masaki N, Obara K, Baranov A, Bouvet M, Tsunoda T, Hoffman RM. Cancer Genomics & Proteomics. 2022 Nov 3;19(6):683–691. doi: 10.21873/cgp.20351

The sympathetic nervous system contributes to the establishment of pre-metastatic pulmonary microenvironments. Ieguchi K, Funakoshi M, Mishima T, Takizawa K, Omori T, Nakamura F, Watanabe M, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Maru Y, Wada S.
International Journal of Molecular Sciences. 2022 Sep 13;23(18):10652. doi: 10.3390/ijms231810652

Emerging immune-monitoring system for immune checkpoint inhibitors.
Hamada K, Tsunoda T, Yoshimura K. Life (Basel). 2022 Aug 13;12(8):1229. doi: 10.3390/life12081229.

Long-term stable disease in a rectal-cancer patient treated by methionine restriction with oral recombinant methioninase and a low-methionine diet. Kubota Y, Han Q, Hamada K, Aoki Y, Masaki N, Obara K, Tsunoda T, Hoffman RM. Anticancer Research. 2022 Aug;42(8):3857–3861. doi: 10.21873/anticanres.15893.

Obesity strongly promotes growth of mouse MC38 colon cancer in an orthotopic-syngeneic C57BL/6 mouse model. Hamada K, Kubota Y, Aoki Y, Sugisawa N, Yamamoto J, Tashiro Y, Bouvet M, Tsunoda T, Hoffman RM. In Vivo. 2022 Jul-Aug;36(4):1643-1646. doi: 10.21873/invivo.12875

Stage IV pancreatic cancer patient treated with FOLFIRINOX combined with oral methioninase: A highly rare case with long-term stable disease. Kubota Y, Han Q, Hozumi C, Masaki N, Yamamoto J, Aoki Y, Tsunoda T, Hoffman RM.　Anticancer Research. 2022 May;42(5):2567–2572. doi: 10.21873/anticanres.15713.

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).Tanaka H, Sakamoto H, Akita T, Ohyanagi F, Kawashima Y, Tambo Y, Tanimoto A, Horiike A, Miyauchi E, Tsuchiya-Kawano Y, Yanagitani N, Nishio M. Thorac Cancer. 2022 May;13(10):1471–1478. doi: 10.1111/1759-7714.14415. Epub 2022 Apr 12

Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.Arai J, Otoyama Y, Fujita KI, Goto K, Tojo M, Katagiri A, Nozawa H, Kubota Y, Takahashi T, Ishida H, Tsunoda T, Matsumoto N, Ogawa K, Nakagawa R, Muroyama R, Kato N, Yoshida H. BMC Cancer. 2022 Apr 20;22(1):428. doi: 10.1186/s12885-022-09512-5.

Update on epidemiology, diagnosis, and biomarkers in gastroenteropancreatic neuroendocrine neoplasms. Takayanagi D, Cho H, Machida E, Kawamura A, Takashima A, Wada S, Tsunoda T, Kohno T, Shiraishi K. Cancers. 2022 Apr;14(9):2205. doi: 10.3390/cancers14092205.

2021年業績

論文（原著）

Verification of the Usefulness of an Assessment and Risk Control Sheet that Promotes Management of Cancer Drug Therapy. Honma O, Watanabe C, Fukuchimoto H, Kashiwazaki J, Tateba M, Wagatsuma S, Ogata K, Maki K, Sonou H, Shiga K, Otsuka E, Hiruta M, Hirasawa Y, Hosonuma M, Murayama M, Narikawa Y, Toyoda H, Tsurui T, Kuramasu A, Kin M, Kubota Y, Sambe T, Horiike A, Ishida H, Shimada K, Umeda M, Tsunoda T, Yoshimura K. Front Pharmacol. 2022 Feb 9;13:744916. doi: 10.3389/fphar.2022.744916. eCollection 2022.

Verification of the usefulness of an assessment and risk control sheet that promotes management of cancer drug therapy. Honma O, Watanabe C, Fukuchimoto H, Kashiwazaki J, Tateba M, Wagatsuma S, Ogata K, Maki K, Sonou H, Shiga K, Otsuka E, Hiruta M, Hirasawa Y, Hosonuma M, Murayama M, Narikawa Y, Toyoda H, Tsurui T, Kuramasu A, Kin M, Kubota Y, Sambe T, Horiike A, Ishida H, Shimada K, Umeda M, Tsunoda T, Yoshimura K.Frontiers in Pharmacology. 2021 Dec;33(4):239–248. doi: 10.15369/sujms.33.239.

Increased plasma soluble PD-1 concentration correlates with disease progression in patients with cancer treated with anti-PD-1 antibodies.Ohkuma R, Ieguchi K, Watanabe M, Takayanagi D, Goshima T, Onoue R, Hamada K, Kubota Y, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Tsurutani J, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S.Biomedicines. 2021 Dec 16;9(12):1929. doi: 10.3390/biomedicines9121929.

Salmonella typhimurium A1-R exquisitely targets and arrests a matrix-producing triple-negative breast carcinoma in a PDOX model. Hamada K, Aoki Y, Yamamoto J, Hozumi C, Zhao M, Murata T, Sugisawa N, Bouvet M, TsunodaT, Hoffman RM.In Vivo. 2021 Nov-Dec;35(6):3067-3071.doi:10.21873/invivo.12602.

First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.Satouchi M, Nosaki K, Takahashi T, Nakagawa K, Aoe K, Kurata T, Sekine A, Horiike A, Fukuhara T, Sugawara S, Umemura S, Saka H, Okamoto I, Yamamoto N, Sakai H, Kishi K, Katakami N, Horinouchi H, Hida T, Okamoto H, Atagi S, Ohira T, Han SR, Noguchi K, Ebiana V, Hotta K. Cancer Sci. 2021 Dec;112(12):5000–5010. doi: 10.1111/cas.15144. Epub 2021 Nov 5.

A high number of PD-L1⁺CD14⁺monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors.Ando K, Hamada K, Shida M, Ohkuma R, Kubota Y, Horiike A, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Watanabe M, Onoue R, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S. Cancer Immunology, Immunotherapy. 2021 Feb;70(2):337-348. doi: 10.1007/s00262-020-02686-6. Epub 2020 Aug 5.Antibiotic usage reduced overall survival by over 70% in non-small cell lung cancer patients on anti-PD-1 immunotherapy.Hamada K, Yoshimura K, Hirasawa Y, Hosonuma M, Murayama M, Narikawa Y, Ariizumi H, Ohkuma R, Shida M, Kubota Y, Matsukuma S, Ishiguro T, Sambe T, Horiike A, Kuramasu A, Wada S, Tsurutani J, Inoue E, Uchida N, Kiuchi Y, Kobayashi S, Hoffman RM, Tsunoda T.
Anticancer Research. 2021 Oct;41(10):4985-4993. doi: 10.21873/anticanres.15312.

The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy. Go Ikeda , Shun Yamamoto , Ken Kato Review Expert Opin Drug Saf. 2022 Jan;21(1):55-65. doi: 10.1080/14740338.2021.1955100. Epub 2021 Jul 26.

Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.
Tsuboya A, Kubota Y, Ishida H, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Sasaki Y, Matsumoto N, Kondo Y, Tomoda Y, Kusuhara H, Fujita KI. Cancer Chemotherapy and Pharmacology. 2021 Sep;88(3):543-553. doi: 10.1007/s00280-021-04314-1. Epub 2021 Jun 11.

A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Hirasawa Y, Yoshimura K, Matsui H, Kubota Y, Ishida H, Arai J, Sakaki M, Oguro N, Shida M, Taniguchi M, Hamada K, Ariizumi H, Ishiguro T, Ohkuma R, Sambe T, Horiike A, Imamura CK, Shiozawa E, Wada S, Tsurutani J, Iwamoto S, Uchida N, Kiuchi Y, Tate G, Kobayashi S, Tsunoda T. Medicine (Baltimore). 2021 Jun 11;100(23):e25774.

Rare nivolumab-associated super hyper progressive disease in patients with advanced gastric cancer.Kubota Y, Yoshimura K, Hamada K, Hirasawa Y, Shida M, Taniguchi M, Matsui H, Ariizumi H, Ishiguro T, Suzuki N, Ohkuma R, Sambe T, Ishida H, Horiike A, Wada S, Tsurutani J, Iwamoto S, Uchida N, Kiuchi Y, Kobayashi S, Tsunoda T. In Vivo. 2021 May-Jun;35(3):1865-1875. doi: 10.21873/invivo.12449.

2020年業績

論文（原著）

Analysis of ADAM12-mediated ephrin-A1 cleavage and its biological functions.
Ieguchi K, Tomita T, Takao T, Omori T, Mishima T, Shimizu I, Tognolini M, Lodola A, Tsunoda T, Kobayashi S, Wada S, Maru Y. International Journal of Molecular Sciences. 2021 Mar 1;22(5):2480. doi: 10.3390/ijms22052480.

Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer. Hasegawa T, Yanagitani N, Ohyanagi F, Kudo K, Horiike A, Tambo Y, Nishikawa S, Ariyasu R, Uchibori K, Kitazono S, Nishio M. Int J Clin Oncol. 2021 Mar;26(3):507–514. doi: 10.1007/s10147-020-01822-7. Epub 2020 Nov 7.

The prognostic impact of eosinophils and the eosinophil-to-lymphocyte ratio on survival outcomes in stage II resectable pancreatic cancer.
Ohkuma R, Kubota Y, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Aoki T, Murakami M, Kobayashi S, Tsunoda T, Wada S.Pancreas. 2021 Feb 1;50(2):167-175. doi: 10.1097/MPA.0000000000001731.

High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer. Ohkuma R, Yada E, Ishikawa S, Komura D, Kubota Y, Hamada K, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Kobayashi S, Tsunoda T, Wada S.
International Journal of Oncology. 2021 Jan;58(1):57-69. doi: 10.3892/ijo.2020.5147. Epub 2020 Nov 12.

A Novel System to Detect Circulating Tumor Cells Using Two Different Size-selective Microfilters.Sonoda T, Yanagitani N, Suga K, Yoshizawa T, Nishikawa S, Kitazono S, Horiike A, Shiba K, Ishizuka T, Nishio M, Matsusaka S. Anticancer Res. 2020 Oct;40(10):5577–5582. doi: 10.21873/anticanres.14570.

Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma.Okuma Y, Goto Y, Ohyanagi F, Sunami K, Nakahara Y, Kitazono S, Kudo K, Tambo Y, Kanda S, Yanagitani N, Horiike A, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Nishio M, Ohe Y, Hosomi Y. Cancer Med. 2020 Oct;9(20):7418–7427. doi: 10.1002/cam4.3385. Epub 2020 Aug 19.

Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High–PD-L1–Expressing Non–Small-Cell Lung Cancer.Hasegawa T, Yanagitani N, Utsumi H, Wakui H, Sakamoto H, Tozuka T, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Uchibori K, Kitazono S, Horiike A, Horai T, Kuwano K, Nishio M. In Vivo. 2020 Sep–Oct;34(5):2997–3003. doi:10.21873/invivo.12131.

Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56. Sakakibara R, Kobayashi M, Takahashi N, Inamura K, Ninomiya H, Wakejima R, Kitazono S, Yanagitani N, Horiike A, Ichinose J, Matsuura Y, Nakao M, Mun M, Nishio M, Okumura S, Motoi N, Ito T, Miyazaki Y, Inase N, Ishikawa Y. Am J Surg Pathol. 2020Jun;44(6):757764.doi:10.1097/PAS.0000000000001444.

High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer. Ohkuma R, Yada E, Ishikawa S, Komura D, Kubota Y, Hamada K, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Kobayashi S, Tsunoda T, Wada S.
Oncology Reports. 2020 Jul;44(1):252-262. doi: 10.3892/or.2020.7610. Epub 2020 May 11.

Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin–treated colorectal cancer patients.Matsumoto N, Kubota Y, Ishida H, Sekido M, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Ikusue T, Kobayashi K, Hisamatsu A, Toshima H, Shimada K, Fujita KI. Cancer Chemotherapy and Pharmacology. 2020 Jun;85(6):1119-1128. doi: 10.1007/s00280-020-04087-z. Epub 2020 May 26.

Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, Azuma K, Yoneshima Y, Murakami H, Hosomi Y, Atagi S, Ozaki T, Horiike A, Fujita Y, Okamoto H, Ando M, Yamamoto N, Ohe Y, Nakagawa K. JAMA Oncol. 2020 May 1;6(5):e196828. doi: 10.1001/jamaoncol.2019.6828. Epub 2020 May 14.15)

化学放射線療法後デュルバルマブの投与回避要因(TOPGAN2020-01).有安 亮,内堀 健,田中 寿志,宮内 栄作,川嶋 庸介,大柳 文義,堀池 篤,酒谷 俊雄,齊木 雅史,丹保 裕一,谷本 梓,園田 智明,神山 潤二,上浪 健,工藤 慶太,土屋 裕子,西尾 誠人.肺癌60(7):2020. 966-971. 2021220379, DOI：10.2482/haigan.60.966
2019年業績

論文（原著）

Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.Tozuka T, Kitazono S, Sakamoto H, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Hasegawa T, Uchibori K, Yanagitani N, Horiike A, Horai T, Seike M, Gemma A, Nishio M. BMC Cancer. 2020 Mar 12;20(1):207. doi: 10.1186/s12885-020-6704-z.

High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. Ohkuma R, Yada E, Ishikawa S, Komura D, Ishizaki H, Tamada K, Kubota Y, Hamada K, Ishida H, Hirasawa Y, Ariizumi H, Satoh E, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Yokobori T, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Izumizaki M, Kobayashi S, Tsunoda T, Wada S.
PLoS ONE. 2020 Jan 10;15(1):e0226707. doi: 10.1371/journal.pone.0226707. eCollection 2020.

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Yanagitani N, Uchibori K, Koike S, Tsukahara M, Kitazono S, Yoshizawa T, Horiike A, Ohyanagi F, Tambo Y, Nishikawa S, Fujita N, Katayama R, Nishio M. Cancer Sci. 2020 Mar;111(3):932–939. doi: 10.1111/cas.14314. Epub 2020 Feb 8.

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).Seto T, Azuma K, Yamanaka T, Sugawara S, Yoshioka H, Wakuda K, Atagi S, Iwamoto Y, Hayashi H, Okamoto I, Saka H, Mitsuoka S, Fujimoto D, Nishino K, Horiike A, Daga H, Sone T, Yamamoto N, Nakagawa K, Nakanishi Y. J Clin Oncol. 2020 Mar 10;38(8):793–803. doi: 10.1200/JCO.19.01494. Epub 2019 Dec 27.

Agranulocytosis during treatment with sulfamethoxazole–trimethoprim and a proton pump inhibitor.Funakoshi H, Momo K, Uchikura T, Ariizumi H, Hamada K, Tsunoda T, Sasaki T.
American Journal of Therapeutics. 2019 Nov 29;28(6):e766-e768. doi: 10.1097/MJT.0000000000001118.

Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients.Kubota Y, Fujita KI, Takahashi T, Sunakawa Y, Ishida H, Hamada K, Ichikawa W, Tsunoda T, Shimada K, Masuo Y, Kato Y, Sasaki Y.Clinical Pharmacology & Therapeutics. 2020 Sep;108(3):586-595. doi:10.1002/cpt.1810. Epub 2020 Mar 10.

Characterization of tumor-infiltrating immune cells in relation to microbiota in colorectal cancers.Kikuchi T, Mimura K, Ashizawa M, Okayama H, Endo E, Saito K, Sakamoto W, Fujita S, Endo H, Saito M, Momma T, Saze Z, Ohki S, Shimada K, Yoshimura K, Tsunoda T, Kono K.Cancer Immunology, Immunotherapy. 2020 Jan;69(1):23-32. doi: 10.1007/s00262-019-02433-6. Epub 2019 Nov 26.

Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer
.Tsuchiya-Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, Hosokawa S, Morinaga R, Komiya K, Inoue K, Fujita Y, Toyozawa R, Kimura T, Takahashi K, Nishikawa K, Kishimoto J, Nakanishi Y, Okamoto I. Oncologist. 2020 Jun;25(6):475–e891. doi: 10.1634/theoncologist.2019-0746. Epub 2019 Oct 24.

Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced non–small cell lung cancer. Amino Y, Kitazono S, Uematsu S, Hasegawa T, Yoshizawa T, Uchibori K, Yanagitani N, Horiike A, Horai T, Kasahara K, Nishio M. International Journal of Clinical Oncology. 2020 Jan;25(1):67–73. doi:10.1007/s10147-019-01537-4. Epub 2019 Sep 10.

Plasma levels of soluble PD-L1 correlate with tumor regression in patients with lung and gastric cancer treated with immune checkpoint inhibitors.Ando K, Hamada K, Watanabe M, Ohkuma R, Shida M, Onoue R, Kubota Y, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S.Anticancer Research. 2019 Sep;39(9):5195-5201. doi: 10.21873/anticanres.13716.

Genetic Profiling of Non–Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
Otsubo K, Sakai K, Takeshita M, Harada D, Azuma K, Ota K, Akamatsu H, Goto K, Horiike A, Kurata T, Nakagaki N, Nosaki K, Iwama E, Nakanishi Y, Nishio K, Okamoto I.
The Oncologist. 2019 Aug;24(8):1022–1026. doi:10.1634/theoncologist.2019-0101. Epub 2019 Apr 25.

Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.Saiki M, Kitazono S, Yoshizawa T, Dotsu Y, Ariyasu R, Koyama J, Sonoda T, Uchibori K, Nishikawa S, Yanagitani N, Horiike A, Ohyanagi F, Oikado K, Ninomiya H, Takeuchi K, Ishikawa Y, Nishio M. Lung Cancer. 2019 Jul;133:4–9. doi:10.1016/j.lungcan.2019.04.022. Epub 2019 Apr 27

Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil.
Sekido M, Fujita KI, Kubota Y, Ishida H, Takahashi T, Ohkuma R, Tsunoda T, Ishikawa F, Shibanuma M, Sasaki Y. Cancer Chemotherapy and Pharmacology. 2019 Jun;83(6):1127-1135. doi: 10.1007/s00280-019-03837-y. Epub 2019 Apr 9.

Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non–small cell lung cancer.Koyama J, Horiike A, Yoshizawa T, Dotsu Y, Ariyasu R, Saiki M, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ninomiya H, Ishikawa Y, Nishio M.
Journal of Thoracic Disease. 2019 May;11(5):1919–1928. doi:10.21037/jtd.2019.04.102

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non–Small-Cell Lung Cancer.Nokihara H, Nishio M, Yamamoto N, Fujiwara Y, Horinouchi H, Kanda S, Horiike A, Ohyanagi F, Yanagitani N, Nguyen L, Yaron Y, Borgman A, Tamura T.
Clinical Lung Cancer. 2019 May;20(3):e317–e328. doi:10.1016/j.cllc.2018.12.018. Epub 2018 Dec 31.

Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status. Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S. Cancer Res. 2019 Apr 1;79(7):1658-1670. doi: 10.1158/0008-5472.CAN-18-2052. Epub 2019 Feb 8.

Improvement in the survival of patients with stage IV non–small-cell lung cancer: Experience in a single institutional 1995–2017. Takano N, Ariyasu R, Koyama J, Sonoda T, Saiki M, Kawashima Y, Oguri T, Hisakane K, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Horiike A, Gemma A, Nishio M.
Lung Cancer. 2019 May;131:69–77. doi:10.1016/j.lungcan.2019.03.008. Epub 2019 Mar 21.